Document Detail

The Impact of Pulmonary Arterial Pressure on Exercise Capacity in Mild-to-Moderate Cystic Fibrosis: A Case Control Study.
Jump to Full Text
MedLine Citation:
PMID:  22900167     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Background. Pulmonary hypertension (PH) is an often complication of severe cystic fibrosis (CF); however, data on the presence and impact of pulmonary vasculopathy in adult CF patients with milder disease, is very limited. Aim. To investigate, for the first time, the impact of systolic pulmonary arterial pressure (PASP) on maximal exercise capacity in adults with mild-to-moderate cystic fibrosis, without PH at rest. Methods. This is a Case Control study. Seventeen adults with mild-to-moderate CF, without PH at rest (cases) and 10 healthy, nonsmoking, age, and height matched controls were studied. All subjects underwent maximal cardiopulmonary exercise testing and echocardiography before and within 1 minute after stopping exercise. Results. Exercise ventilation parameters were similar in the two groups; however, cases, compared to controls, had higher postexercise PASP and decreased exercise capacity, established with lower peak work rate, peak O(2) uptake, anaerobic threshold, and peak O(2) pulse. Furthermore, the change in PASP values before and after exercise was strongly correlated to the parameters of exercise capacity among cases but not among controls. Conclusions. CF adults with mild-to-moderate disease should be screened for the presence of pulmonary vasculopathy, since the elevation of PASP during exercise might contribute to impaired exercise capacity.
Katerina Manika; Georgia G Pitsiou; Afroditi K Boutou; Vassilis Tsaoussis; Nikolaos Chavouzis; Marina Antoniou; Maria Fotoulaki; Ioannis Stanopoulos; Ioannis Kioumis
Related Documents :
18552297 - The responses of atlantic cod (gadus morhua l.) to ultrasound-emitting predators: stres...
14651947 - Effects of acute stress, relaxation, and a neurogenic inflammatory stimulus on interleu...
3465637 - Role of aerobic exercise in reduction of stress.
439157 - Endurance, strength, and coordination exercises without cardiovascular or respiratory s...
9056027 - Modeling the effects of exercise during 100% oxygen prebreathe on the risk of hypobaric...
2205777 - Endorphins and exercise: physiological mechanisms and clinical implications.
Publication Detail:
Type:  Journal Article     Date:  2012-07-29
Journal Detail:
Title:  Pulmonary medicine     Volume:  2012     ISSN:  2090-1844     ISO Abbreviation:  Pulm Med     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-17     Completed Date:  2012-08-23     Revised Date:  2013-04-02    
Medline Journal Info:
Nlm Unique ID:  101558762     Medline TA:  Pulm Med     Country:  Egypt    
Other Details:
Languages:  eng     Pagination:  252345     Citation Subset:  -    
Pulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" General Hospital, Exohi, 57010 Thessaloniki, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Pulm Med
Journal ID (iso-abbrev): Pulm Med
Journal ID (publisher-id): PM
ISSN: 2090-1836
ISSN: 2090-1844
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2012 Katerina Manika et al.
Received Day: 30 Month: 11 Year: 2011
Accepted Day: 10 Month: 6 Year: 2012
Print publication date: Year: 2012
Electronic publication date: Day: 29 Month: 7 Year: 2012
Volume: 2012E-location ID: 252345
ID: 3414060
PubMed Id: 22900167
DOI: 10.1155/2012/252345

The Impact of Pulmonary Arterial Pressure on Exercise Capacity in Mild-to-Moderate Cystic Fibrosis: A Case Control Study
Katerina Manika1
Georgia G. Pitsiou2*
Afroditi K. Boutou2
Vassilis Tsaoussis1
Nikolaos Chavouzis2
Marina Antoniou1
Maria Fotoulaki3
Ioannis Stanopoulos2
Ioannis Kioumis1
1Pulmonary Department, Aristotle University of Thessaloniki, “G. Papanikolaou” General Hospital, Exohi, 57010 Thessaloniki, Greece
2Respiratory Failure Unit, Aristotle University of Thessaloniki, “G. Papanikolaou” General Hospital, Exohi, 57010 Thessaloniki, Greece
34th Department of Pediatrics, Aristotle University of Thessaloniki, “Papageorgiou” General Hospital, 56429 Thessaloniki, Greece
Correspondence: *Georgia G. Pitsiou:
[other] Academic Editor: Robert Naeije

1. Introduction

Exercise impairment in cystic fibrosis (CF) is well established and a variety of determinants, such as pulmonary and nutritional factors, muscle dysfunction and deconditioning, have been studied in this direction [14]. It seems that the factors which are limiting exercise tend to vary across disease stages; ventilatory impairment is probably the major factor limiting exercise in severe disease, while nonpulmonary factors seem to be related to reduced exercise capacity in mild and moderate disease [4].

Pulmonary hypertension (PH), which is a common determinant of exercise capacity in patients with respiratory disorders [5], is an often complication of CF. PH is observed in 20–65% of adult CF patients with severe disease [610], and it has been associated with increased mortality [6, 11]. However, data on its frequency and impact among patients with milder disease are limited. Although adult CF patients with mild-to-moderate disease achieve maximum exercise without generally reaching ventilatory limitation [4], the potential effect of pulmonary vasculopathy on exercise capacity, in this patient population, has not yet been clarified.

In this study we hypothesized that pulmonary vascular disease contributes to the exercise intolerance of adult CF patients with mild-to-moderate disease, without PH at rest. Under this scope we conducted a case-control study, utilizing maximal cardiopulmonary exercise testing (CPET), in order to investigate, for the first time in literature, the impact of post exercise PASP on this patient population.

2. Methods
2.1. Subjects

The study followed a case-control design. Seventeen adult CF patients with mild-to-moderate disease constituted the group of cases and 10 healthy nonsmoking volunteers matched for age and height, constituted the group of controls. All CF patients were regularly attending the outpatient CF clinic of “G. Papanikolaou” Hospital, were in stable clinical condition and were life-long nonsmokers. Mild pulmonary disease was defined by the presence of FEV1 >65% of predicted, and moderate disease by the presence of ≤40% FEV1 ≤65% of predicted [6]. Patients who presented with an exacerbation of the disease, that is increased sputum production, purulence, or dyspnea with or without systemic symptoms, combined with a 10% or more reduction in patient's forced expiratory volume in 1 second (FEV1) usual value, were excluded from the study. Patients who were hospitalized or required per os antibiotics during the last 2 months prior to the study, received domiciliary oxygen therapy, or presented with any other condition affecting exercise capacity, were also excluded. Ethical approval for the study protocol was received from the “G. Papanikolaou” Hospital Scientific Committee and informed consent was provided by all participants.

2.2. Study Protocol

During the baseline visit, all CF patients were clinically assessed by the same physician, who documented their Schwachmann score (SS). An arterial blood sample was obtained for both cases and controls, while all participants underwent pulmonary function testing. Forced vital capacity (FVC) and FEV1 were measured utilizing an electronic spirometer (Wright ventilometer, Clement Clarke International Ltd., England), according to the American Thoracic Society recommendations [12].

All participants visited again the CF clinic within one week and underwent a complete transthoracic echocardiographic study, including 2D, pulsed and continuous-wave Doppler and colour flow imaging using a HD7 cardiac ultrasound system (Philips medical system, Andover, MA, USA). Standard two-dimensional (2D) and colour flow Doppler images were obtained using the parasternal long and short axis and apical views. PASP was estimated by calculating the maximal velocity of the tricuspid regurgitant jet and by further using the Bernoulli equation and then adding to this value an estimated right atrial pressure based on both the size of the inferior vena cava and the change in diameter of this vessel during respiration. PH was defined as a PASP >35 mmHg at rest [13]. Left ventricular dimensions, ejection fraction, and cardiac index were obtained by previously recommended techniques [14].

A maximal exercise capacity test was then performed on a cycle ergometer (medical graphics), under continuous monitoring of heart rate (HR), oxygen saturation (SpO2), and a 12-lead electrocardiogram, while blood pressure (BP) measurements were obtained every two minutes using a standard-cuff mercury sphygmomanometer. A ramp protocol was used with an incremental rate of 20 Watts·min−1 for controls and of 10–20 Watts·min−1 for cases according to disease severity and estimated fitness, aiming for the test to last approximately 10–12 minutes [15]. Each test was preceded by 3 min of resting to enable subjects to achieve steady state conditions for HR, SpO2, BP, and gas exchange variables, and of 2 min of unloaded cycling. Patients and controls were asked to score their sense of dyspnea and muscle fatigue using Borg scale, every 2 minutes during the test.

Gas exchange values and exercise parameters were collected breath-by-breath and computer-averaged over 10-second intervals. Anaerobic threshold was calculated by the V slope method, as previously described [15]. The following exercise parameters were recorded: maximal work rate (WR peak), peak oxygen uptake (VO2 peak), oxygen uptake at anaerobic threshold (AT), peak oxygen pulse (VO2 peak/HR), ventilatory equivalent for carbon dioxide at AT (VE/VCO2), maximal ventilation VEmax, peak heart rate (HR), maximum minute ventilation to maximum voluntary ventilation ratio (VEmax/MVV), and breathing reserve (BR). The MVV was calculated as 40 × FEV1 and the breathing reserve as MVV-VEmax. Ventilatory limitation was defined as (VEmax/MVV) × 100 > 85% or BR <11 lit [15, 16].

Within 1 minute after the completion of the exercise testing, a second echocardiogram was performed by the same investigator, following the same protocol and focusing on postexercise tricuspid regurgitation velocity.

2.3. Data Analysis

Data analysis was conducted using the Statistical Package for Social Sciences (SPSS) for Windows 2000XP, release 17.0. Normal predicted values for CPET parameters were calculated using standard equations [15, 16]. The Shapiro-Wilk test of normality was used to assess the normal or not distribution of data. Student's t-test for independent samples was used to compare CPET parameters between cases and controls, while the Mann-Whitney the U-test was applied to compare CPET parameters between CF patients with low (≤35 mmHg) and high (>35 mmHg) postexercise PASP. ΔSPAP was calculated as follows: PASP after exercise − PASP at rest. Pearson correlation coefficient (r) was used to assess potential correlations between ΔPASP and CPET parameters in cases and controls. A P value <0.05 was considered significant.

3. Results

Summary characteristics of cases and controls are shown in Tables 1 and 2. During rest, none of the CF patients suffered from PH and no difference was noted in PASP or any other echocardiographic measurement between the two groups. However, PASP immediately after exercise was significantly higher in the group of cases compared to controls (31.5 versus 25.8, P = 0.041).

Both cases and controls stopped exercise because of fatigue. At the end of exercise mean Borg scale for fatigue was approximately 8 and mean Borg scale for dyspnea was 6 for both groups. Respiratory exchange ratio (RER) at peak exercise was >1.1 for all subjects. During maximal CPET, CF patients presented limited exercise capacity, compared to controls, as established by lower WR, VO2 peak, AT, and oxygen pulse (Table 2). However, no participant presented with respiratory limitation. Although the absolute value of MVV-VEmax was higher among cases compared to controls, VEmax/MVV% predicted did not differ between the two groups and even though BR was significantly lower among cases (Table 2), it was higher than 11 liters in all participants. Oxygen saturation at peak exercise was also similar between the two groups (Table 2).

After exercise, 5 cases presented with PASP >35 mmHg and the rest 12 cases with PASP ≤35 mmHg, while all controls had PASP ≤35 mmHg. No difference was noted between the two CF patient groups with and without exercise-induced PH, regarding FEV1% predicted and FVC% predicted values (data not shown). Those CF patients with post exercise PASP >35 mmHg exhibited lower WR peak% predicted, VO2 peak% predicted, VO2/HR% predicted, and SpO2 peak, and a trend for higher VE/VCO2@AT, compared to the rest of CF patients. However, none of the parameters indicative of ventilatory limitation during exercise, that is VEmax, VEmax/MVV and BR differed between CF patients with and without postexercise PH (Table 3).

In cases, but not in controls, ΔSPAP established an inverse, strong correlation to several parameters of exercise capacity, that is, WR peak (watts and % predicted), VO2 peak (mL/kg∗min and % predicted), oxygen pulse (mL/kg∗beats and % predicted), and SpO2 peak (Table 4). ΔSAP was also strongly correlated to Schwachman score (Spearman rho = −0.698, P = 0.002) in the group of cases. On the contrary, neither pulmonary function testing parameters, nor any variable indicative of ventilatory limitation during exercise was correlated to ΔSPAP, in any of the groups (data not shown).

4. Discussion

The main findings of our study are (a) patients with mild-to-moderate CF without PH at rest, exhibit higher postexercise PASP and lower exercise capacity compared to controls, without reaching ventilatory limitation, (b) exercise impairment and dyspnea are probably more pronounced among CF patients with higher (≥35 mmHg) postexercise PASP, and (c) ΔPASP is inversely correlated with maximal work rate and oxygen uptake in cases, but not in controls.

The association of PH and exercise tolerance in mild-to-moderate CF is far from clear. Montgomery et al. have reported the case of a CF adult patient with severe lung disease and pulmonary hypertension that increased significantly after exercise and improved with sildenafil treatment [17]. Although recently published data demonstrate that CF patients suffer from endothelial dysfunction and defective dilatation of pulmonary vessels during exercise [18], in another study the estimated rest PASP was not correlated to submaximal exercise capacity among CF patients with both severe and moderate disease [19]. However, there is no data regarding the exercise-induced increase of pulmonary artery pressure and its possible impact on maximum exercise tolerance, in patients with less severe disease and no evident pulmonary vasculopathy at rest.

In this study, a group of mild-to-moderate CF patients without PH at rest exhibited a higher postexercise PASP, a lower exercise capacity and a higher VE/VCO2 ratio at anaerobic threshold compared to controls, although both groups terminated exercise due to fatigue, without presenting respiratory limitation. VE/VCO2 is considered to be a noninvasive marker of pulmonary vascular resistance [20] and previous studies have reported a significant increase in the VE/VCO2 slope, during exercise, both in CF patients [1] and in patients with severe PH [21]. During maximal CPET, both dyspnea and exercise limitation were even more pronounced among patients with higher (>35 mmHg) postexercise PASP values, compared to the rest of the patients. Furthermore, ΔPASP values correlated to peak work rate, peak O2 uptake, O2 pulse and SpO2 at peak exercise only in the group of cases, while no correlation was noted to any measurement of ventilation during exercise. These data indicate that in CF patients with less severe disease, pulmonary circulation could be defective, resulting to impaired exercise capacity, regardless of the patients' respiratory reserve.

As in several chronic respiratory diseases, exercise capacity in adult CF patients could also be influenced by suboptimal nutritional status and muscle dysfunction [22, 23]. Malnutrition results, through a loss of muscle mass, to a reduction in every day activities and to peripheral muscle deconditioning [23]. The current study was not designed to control for these confounders, so their specific impact on exercise limitation could not be assessed. However, patients and controls weighted the same, since they were height-matched and had the same BMI, which indicates that their nutritional status was similar. Moreover, there was no difference in peak Borg fatigue score neither between patients and controls, nor between patients with and without exercise induced PH, indicating a similar peripheral muscle effort. These results come to an agreement with a previous study where differences in Borg scores of muscle effort and lactic acid were noted only in the group of CF patients with severe respiratory limitation and not among those with mild and moderate disease [4]. Future studies are needed to assess the exact impact of pulmonary vasculopathy on exercise capacity in these patient group, independently of nutritional status and muscle dysfunction.

There are certain limitations in this study. The number of participants who were included was quite small. However, our findings regarding exercise performance are very similar to the ones from larger cohorts [2]. Moreover, although the “gold standard” for measurement of pulmonary artery pressure remains right heart catheterization, Doppler echocardiography has proved to be an easily accessible, noninvasive alternative in previous studies [24]. Another limitation is that PASP is very much affected by cardiac output, so a higher postexercise PASP might reflect not a pulmonary vascular disease but just a persistently higher cardiac index; however there is no sufficient explanation as to why this could be established in cases but not in controls. Furthermore, cardiac output and PASP rapidly recover after exercise in a variable and non-proportional rate [25] and Argiento et al. have previously reported that this could be a reason why post-exercise measurements may be problematic [26]. However, in the latter study, PASP was estimated 5 to 20 minutes after exercise, while in the current study all measurements were conducted within 60 seconds. Although the method adopted in our study may still estimate PASP values less accurately than echocardiography during exercise [25], it has been previously used in order to assess pulmonary hypertension among scleroderma patients and was found to correlate well with several parameters of exercise capacity [27, 28].

In conclusion, pulmonary vascular disease, as established by high post exercise PASP, might be added to the list of determinants of both exercise impairment and increased dyspnea among CF patients with mild-to-moderate disease. To our knowledge, this study is the first to directly investigate the potential association between estimated PASP and maximal exercise capacity in these patients. The limitation in physical functioning and the increased dyspnea are the two primary parameters which affect quality of life in CF patients [29]. Under this scope, further studies, including a larger number of patients with different stages of disease severity are needed, in order for the contribution of pulmonary vascular disease in the physical impairment of this population to be fully evaluated.

Conflict of Interests

The authors declare that they have no conflict of interests.

1. Moser C,Tirakitsoontorn P,Nussbaum E,Newcomb R,Cooper DM. Muscle size and cardiorespiratory response to exercise in cystic fibrosisAmerican Journal of Respiratory and Critical Care MedicineYear: 20001625182318272-s2.0-003369513511069820
2. Shah AR,Gozal D,Keens TG. Determinants of aerobic and anaerobic exercise performance in cystic fibrosisAmerican Journal of Respiratory and Critical Care MedicineYear: 19981574114511502-s2.0-00319683239563732
3. Pouliou E,Nanas S,Papamichalopoulos A,et al. Prolonged oxygen kinetics during early recovery from maximal exercise in adult patients with cystic fibrosisChestYear: 20011194107310782-s2.0-003492429511296172
4. Moorcroft AJ,Dodd ME,Morris J,Webb AK. Symptoms, lactate and exercise limitation at peak cycle ergometry in adults with cystic fibrosisEuropean Respiratory JournalYear: 20052561050105615929961
5. Boutou AK,Pitsiou GG,Trigonis I,et al. Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertensionRespirologyYear: 20111634514582-s2.0-7995328826621122030
6. Fraser KL,Tullis DE,Sasson Z,Hyland RH,Thornley KS,Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemiaChestYear: 19991155132113282-s2.0-003289481810334147
7. Rovedder PME,Ziegler B,Pinotti AFF,Barreto SSM,Dalcin PDTR. Prevalence of pulmonary hypertension evaluated by Doppler echocardiography in a population of adolescent and adult patients with cystic fibrosisJornal Brasileiro de PneumologiaYear: 200834283902-s2.0-4154909228318345451
8. Florea VG,Florea ND,Sharma R,et al. Right ventricular dysfunction in adult severe cystic fibrosisChestYear: 20001184106310682-s2.0-003379357811035678
9. Vizza CD,Lynch JP,Ochoa LL,Richardson G,Trulock EP. Right and left ventricular dysfunction in patients with severe pulmonary diseaseChestYear: 199811335765832-s2.0-00318880409515827
10. Ionescu AA,Payne N,Obieta-Fresnedo I,Fraser AG,Shale DJ. Subclinical right ventricular dysfunction in cystic fibrosis: a study using tissue Doppler echocardiographyAmerican Journal of Respiratory and Critical Care MedicineYear: 20011635121212182-s2.0-003503583611316661
11. Eckles M,Anderson P. Cor pulmonale in cystic fibrosisSeminars in Respiratory and Critical Care MedicineYear: 20032433233302-s2.0-003833688816088553
12. American Thoracic SocietyStandardization of spirometry (1994 update)American Journal of Respiratory and Critical Care MedicineYear: 1995152110711367663792
13. Galiè N,Hoeper MM,Humbert M,et al. Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory JournalYear: 2009346121912632-s2.0-7034963439719749199
14. Schiller NB. Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of EchocardiographyCirculationYear: 1991843I280I2872-s2.0-00260760531884497
15. Wasserman K,Hansen JE,Sue DY,Stringer WW,Whipp BJ. Wasserman K,Hansen JE,Sue DY,Stringer WW,Whipp BJMeasurements during integrative cardiopulmonary exercise testingPrinciples of Exercise-Testing and InterpretationYear: 20054th editionPhiladelphia, Pa, USALippincott Williams and Wilkins76110
16. American Thoracic Society/American College of Chest PhysiciansStatement on cardiopulmonary exercise testingAmerican Journal of Respiratory and Critical Care MedicineYear: 2001167211277
17. Montgomery GS,Sagel SD,Taylor AL,Abman SH. Effects of sildenafil on pulmonary hypertension and exercise tolerance in severe cystic fibrosis-related lung diseasePediatric PulmonologyYear: 20064143833852-s2.0-3364531151116479610
18. Henno P,Maurey C,Danel C,et al. Pulmonary vascular dysfunction in endstage cystic fibrosis: role of NF-κB and endothelin-1European Respiratory JournalYear: 2009346132913372-s2.0-7324912608919460784
19. Rovedder PME,Ziegler B,Pasin LR,et al. Doppler echocardiogram, oxygen saturation and submaximum capacity of exercise in patients with cystic fibrosisJournal of Cystic FibrosisYear: 2007642772832-s2.0-3434727379417157083
20. Ting H,Sun XG,Chuang ML,Lewis DA,Hansen JE,Wasserman K. A noninvasive assessment of pulmonary perfusion abnormality in patients with primary pulmonary hypertensionChestYear: 200111938248322-s2.0-003508973811243964
21. Sun XG,Hansen JE,Oudiz RJ,Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertensionCirculationYear: 200110444294352-s2.0-003594301411468205
22. Gea J,Casadevall C,Pascual S,Orozco-Levi M,Barreiro E. Respiratory diseases and muscle dysfunctionExpert Review of Respiratory MedicineYear: 201261759022283581
23. Lands LC,Heigenhauser GJF,Jones NL. Analysis of factors limiting maximal exercise performance in cystic fibrosisClinical ScienceYear: 19928343913972-s2.0-00267328451330400
24. Homma A,Anzueto A,Peters JI,et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantationJournal of Heart and Lung TransplantationYear: 20012088338392-s2.0-003489826211502405
25. Naeije R. In defence of exercise stress test for the diagnosis of pulmonary hypertensionHeartYear: 2011972949521097521
26. Argiento P,Chesler N,Mulè M,et al. Exercise stress echocardiography for the study of the pulmonary circulationEuropean Respiratory JournalYear: 2010356127312782-s2.0-7795350969719926746
27. Steen V,Chou M,Shanmugam V,Mathias M,Kuru T,Morrissey R. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosisChestYear: 200813411461512-s2.0-4754910170718403670
28. Alkotob ML,Soltani P,Sheatt MA,et al. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with sclerodermaChestYear: 200613011761812-s2.0-3374635936216840399
29. de Jong W,Kaptein AA,van der Schans CP,et al. Quality of life in patients with cystic fibrosisPediatric PulmonologyYear: 1997232951009065946

Article Categories:
  • Clinical Study

Previous Document:  Contractile Activity Regulates Inducible Nitric Oxide Synthase Expression and NO(i) Production in Ca...
Next Document:  Lung cancer and interstitial lung diseases: a systematic review.